Adams Wealth Management’s Theravance Biopharma TBPH Stock Holding History

Adams Wealth Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-7	Closed	–	–	299
2020 Q3	$0	Buy	+7	New	+$131	﹤0.01%	368

Other funds holding TBPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adams Wealth Management's TBPH Position: Q4 2020 in Review

Adams Wealth Management sold out of Theravance Biopharma (TBPH) in Q4 2020, closing a stake of 7 shares.

Adams Wealth Management first reported a position in TBPH in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 107 funds tracked by Wall St. Rank hold TBPH as of Q4 2020.

Adams Wealth Management reported no remaining Theravance Biopharma position as of Q4 2020 after selling out during the quarter.
Adams Wealth Management sold 7 Theravance Biopharma shares in Q4 2020.
Adams Wealth Management first reported a position in Theravance Biopharma in Q3 2020 and held it in 1 quarter.
Adams Wealth Management's Theravance Biopharma position peaked at $0 in Q3 2020.
107 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2020.

Based on Adams Wealth Management's 13F filing for Q4 2020, filed 8 Feb 2021.